SPDR S&P BIOTECH ETF

No trades

See on Supercharts

Overview

Analysis News Ideas

SSGF chart

Key stats

Assets under management (AUM)

‪5.94 B‬EUR

Fund flows (1Y)

—

Dividend yield (indicated)

0.02%

Discount/Premium to NAV

—

About SPDR S&P BIOTECH ETF

Issuer

State Street Corp.

Brand

SPDR

Expense ratio

0.35%

Home page

us.spdrs.com

Inception date

Jan 31, 2006

Index tracked

S&P Biotechnology Select Industry

Management style

Passive

XBI provides exposure to US biotech stocks, as defined by GICS, from a universe that invests across the market-cap spectrum. The fund equal-weights its portfolio, which in turn emphasizes small- and micro-caps and greatly reduces single-name risk. Thus, the weighted-average market-cap is much smaller than some competitors. Unlike other funds in this segment, XBI is a pure biotech play, with relatively small pharma overlap. The index is rebalanced quarterly.